{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:08:33Z","timestamp":1791724113713,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ygyno.2018.05.001","type":"journal-article","created":{"date-parts":[[2018,5,6]],"date-time":"2018-05-06T06:58:28Z","timestamp":1525589908000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis"],"prefix":"10.1016","volume":"150","author":[{"given":"Clemens B.","family":"Tempfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Giger-Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9773-6430","authenticated-orcid":false,"given":"Veronika","family":"Seebacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Askin","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0852-6002","authenticated-orcid":false,"given":"G\u00fcnther A.","family":"Rezniczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.05.001_bb0005","first-page":"288","article-title":"Recurrent epithelial ovarian cancer: an update on treatment","volume":"27","author":"Foley","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0010","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0015","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0025","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1525-1438.2007.01163.x","article-title":"Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature","volume":"18","author":"Gadducci","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0035","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1055\/s-2008-1026541","article-title":"Uber die Vertr\u00e4glichkeit einer intraoperativen, intraperitonealen Chemotherapie bei fortgeschrittenen gyn\u00e4kologischen Malignomen [Tolerance of intraoperative, intraperitoneal chemotherapy in advanced gynecologic malignancies]","volume":"48","author":"Werner","year":"1988","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0040","first-page":"395","article-title":"Emerging treatment options for management of malignant ascites in patients with ovarian cancer","volume":"4","author":"Eskander","year":"2012","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0045","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure","volume":"89","author":"Dedrick","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s004649900010","article-title":"Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator","volume":"14","author":"Reymond","year":"2000","journal-title":"Surg. Endosc."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0055","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/00001813-199607000-00016","article-title":"Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration","volume":"7","author":"Jacquet","year":"1996","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","article-title":"High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis","volume":"244","author":"Esquis","year":"2006","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0065","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","article-title":"Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept","volume":"26","author":"Solass","year":"2012","journal-title":"Surg. Endosc."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0070","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","article-title":"Description of a novel approach for intraperitoneal drug delivery and the related device","volume":"26","author":"Solass","year":"2012","journal-title":"Surg. Endosc."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0075","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/bjs.10521","article-title":"Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis","volume":"104","author":"Grass","year":"2017","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0080","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1245\/s10434-013-3039-x","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects","volume":"20","author":"Solass","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0085","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0090","author":"National Cancer Institute"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ygyno.2013.11.022","article-title":"Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience","volume":"132","author":"Tempfer","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0100","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1245\/s10434-012-2840-2","article-title":"Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"20","author":"Blanco","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0105","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","article-title":"HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer","volume":"136","author":"Zivanovic","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0110","author":"National Institutes of Health"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0115","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1007\/s00261-013-0013-9","article-title":"Accuracy of MDCT in the preoperative definition of Peritoneal Cancer Index (PCI) in patients with advanced ovarian cancer who underwent peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"38","author":"Mazzei","year":"2013","journal-title":"Abdom. Imaging"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s003840050072","article-title":"Pathological features of rectal cancer after preoperative radiochemotherapy","volume":"12","author":"Dworak","year":"1997","journal-title":"Int. J. Color. Dis."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186709","article-title":"Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma","volume":"12","author":"Khosrawipour","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0135","series-title":"Fifth Berkeley Symposium on Mathematical Statistics and Probability","first-page":"855","article-title":"Mouse to man: statistical problems in bringing a drug to clinical trial","author":"Schneiderman","year":"1967"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12885-016-3004-8","article-title":"Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report","volume":"17","author":"Tempfer","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2018.05.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4596176","article-title":"Impact of pressurized intraperitoneal aerosol chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a retrospective cohort study","volume":"2017","author":"Teixeira Farinha","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0150","first-page":"6723","article-title":"Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal carcinomatosis: a cohort study","volume":"35","author":"Tempfer","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2018.05.001_bb0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00007691-199502000-00005","article-title":"Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors","volume":"17","author":"Bonetti","year":"1995","journal-title":"Ther. Drug Monit."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818308515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818308515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T11:09:38Z","timestamp":1720264178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818308515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0090825818308515"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}